#Gilead Sciences

Sovaldi (sofosbuvir) plus the new hep C drug ravidasvir cured 97 percent of those with a range of genotypes in a recent study.

A study in Glasgow provided treatment to those receiving opioid substitution therapy for opioid addiction.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

In a recent trial, 12 weeks of the drug combination worked well regardless of whether individuals had drug-resistant virus.

The drugmaker is accused of infringing on a patent held by rival Merck & Co. over its formulas for Sovaldi and Harvoni treatment.

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

In early research in cell cultures and mice, scientists found Sovaldi could possibly thwart Zika’s harmful effects on unborn babies.

A roundup of key findings from the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC

Thanks to a $1.375 million grant, testing for the viruses at one emergency department has already increased 5,000 percent.

Among a large group treated with minimal or no liver fibrosis, liver-health problems were almost nonexistent up to three years later.

Those with stage 3 CKD saw their kidney function improve after treatment with various combo regimens, including Harvoni.

The World Health Organization (WHO) has added a new hepatitis C treatment to its updated 2017 Essential Medicines List.